Healthcare Industry News: Healthpoint
News Release - May 22, 2006
HEALTHPOINT Launches New Spray Emulsion Delivery FormAwarded Arthritis Foundation 'Ease-of-Use' Commendation
FORT WORTH, Texas, May 22 (HSMN NewsFeed) -- Healthpoint today announced the launch of a new spray emulsion (SE) delivery form for two of its most widely-used wound care treatments, ACCUZYME® (Papain, Urea) and PANAFIL® (Papain, Urea, Chlorophyllin Copper Complex Sodium). In conjunction with the launch, the Arthritis Foundation awarded the products its "Ease-of-Use" Commendation, recognizing the new delivery form with its user-friendly design. ACCUZYME SE and PANAFIL SE are the first wound care treatments to receive this commendation from the Arthritis Foundation.
"The new spray emulsion for ACCUZYME and PANAFIL represent a significant advance in wound care treatment," said Sarah Young, Product Manager at Healthpoint. "These 'no touch' delivery forms are designed to reduce the risk of infection and disturbance to wounds, while offering an efficient and convenient method of delivery. Given that many patients with difficult to heal and chronic wounds may also suffer from arthritis, we are particularly thrilled that the Arthritis Foundation recognized our product design with its "Ease-of-Use" Commendation."
The new spray emulsion provides a continuous spray resulting in a "no touch" application delivery form. Since this treatment does not need to be applied with a tongue applicator, cotton swab or human hands, risks of introducing pathogens that could lead to infection or disturbing a healing wound bed are minimized. The SE canisters provide added convenience because the continuous spray allows both healthcare professionals and patients to apply the treatments at a variety of angles, simplifying access to wounds in harder-to-reach locations.
The "no touch" application technique is recommended by the Association for Professionals in Infection Control and Epidemiology (APIC) and the Wound, Ostomy and Continence Nurses Society (WOCN) as a strategy for reducing infection risk in difficult to heal and chronic wounds.(1)
"The Arthritis Foundation 'Ease-of-Use' Commendation is awarded after a thorough and careful review process by an independent third-party laboratory," said John H. Klippel, M.D., President and CEO of the Arthritis Foundation. "We are pleased to be able to include this type of container innovation into our list of products that are appropriate for individuals living with arthritis."
The SE products will join the current ointment and pump spray formulations of ACCUZYME and PANAFIL, providing healthcare professionals with an array of options that can be selected based on specific patient needs.
About ACCUZYME®(Papain, Urea) Ointment/Spray/Spray Emulsion (SE)
ACCUZYME is the number-one selling enzymatic debrider and is the preferred treatment when surgical debridement is inappropriate or unavailable. Its papain-urea formulation effectively liquifies a variety of denatured, non-viable proteins, including fibrin, collagen, and elastin, without harming healthy, viable tissue.
ACCUZYME is effective and well-tolerated in a variety of partial and full-thickness wounds including diabetic ulcers, pressure ulcers, venous ulcers, infected wounds, postoperative wounds, traumatic wounds, burns, carbuncles, and pilonidal cyst wounds. Upon application, a small percentage of patients may occasionally experience a brief stinging sensation when using ACCUZYME.
About PANAFIL® (Papain, Urea, Chlorophyllin Copper Complex Sodium) Ointment/Spray/Spray Emulsion (SE)
PANAFIL is a dual-action wound therapy used most effectively when granulation tissue is apparent and the wound requires both the maintenance of a healthy wound bed and the nurturing effects of pro-healing ingredients. PANAFIL combines the enzymatic debridement activity of papain-urea with the pro-healing properties of its chlorophyllin copper complex. PANAFIL safely and effectively controls necrotic tissue, reduces the risk of infection, and promotes healing in a variety of partial and full-thickness wound types including diabetic ulcers, pressure ulcers, venous ulcers, infected wounds, postoperative wounds, traumatic wounds, burns, carbuncles, and pilonidal cyst wounds. Upon application, a small percentage of patients may occasionally experience a brief stinging sensation when using PANAFIL.
About Arthritis Foundation and its "Ease-of-Use" Commendation Program
The Arthritis Foundation is the only nationwide, nonprofit health organization helping people take greater control of arthritis by leading efforts to prevent, control and cure arthritis and related diseases -- the nation's number one cause of disability. The Arthritis Foundation is the largest non-governmental funder of arthritis research in the world. Since 1948, the Arthritis Foundation has provided more than $350 million to arthritis-related research through its nationally recognized peer-review research award program. For more information, contact the Arthritis Foundation at 800-568-4045 or www.arthritis.org.
The Arthritis Foundation created the "Ease-of-Use" Commendation Program to encourage manufacturers to design user-friendly products and packaging. Manufacturers submit their product(s) for testing by an independent lab experienced in the design and evaluation of products that are accessible to people with functional limitations due to the effects of arthritis.
About Healthpoint, Ltd.
Since its inception in 1992, Healthpoint has established a presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for surgical, tissue management, and dermatology indications. An aggressive research and development effort has brought Healthpoint's unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. Healthpoint, with over 300 employees, is a DFB Pharmaceuticals, Inc. affiliate company. Healthpoint is based in Fort Worth, Texas.
Also headquartered in Fort Worth, DFB Pharmaceuticals, Inc., provides technology-driven products, outsourcing services, and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.
(1) APIC/WOCN Position Statement. Clean vs. sterile: Management of chronic wounds. APIC News. 2001;March/April:20-31.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.